ATE232212T1 - Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden - Google Patents

Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden

Info

Publication number
ATE232212T1
ATE232212T1 AT97920610T AT97920610T ATE232212T1 AT E232212 T1 ATE232212 T1 AT E232212T1 AT 97920610 T AT97920610 T AT 97920610T AT 97920610 T AT97920610 T AT 97920610T AT E232212 T1 ATE232212 T1 AT E232212T1
Authority
AT
Austria
Prior art keywords
ospc
lys
seq
acid residues
disclosed
Prior art date
Application number
AT97920610T
Other languages
English (en)
Inventor
Marianne Jartved Mathiesen
Michael Theisen
Arne Holm
Soren Ostergaard
Original Assignee
Dako As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako As filed Critical Dako As
Application granted granted Critical
Publication of ATE232212T1 publication Critical patent/ATE232212T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97920610T 1996-05-02 1997-05-02 Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden ATE232212T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK52696 1996-05-02
PCT/DK1997/000203 WO1997042221A1 (en) 1996-05-02 1997-05-02 Novel osp-c derived peptide fragments

Publications (1)

Publication Number Publication Date
ATE232212T1 true ATE232212T1 (de) 2003-02-15

Family

ID=8094548

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97920610T ATE232212T1 (de) 1996-05-02 1997-05-02 Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden

Country Status (6)

Country Link
EP (1) EP0896583B1 (de)
AT (1) ATE232212T1 (de)
CA (1) CA2253374C (de)
DE (2) DE896583T1 (de)
DK (1) DK0896583T3 (de)
WO (1) WO1997042221A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
EP0949508A1 (de) * 1998-04-08 1999-10-13 Dako A/S Verfahren, Antigen-Komplex und Satz zur Diagnose Lyme-Borreliose
ATE386805T1 (de) * 1998-07-31 2008-03-15 Gundersen Lutheran Medical Fou Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
ATE254137T1 (de) * 1998-09-29 2003-11-15 Statens Seruminstitut ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
EP1194559B1 (de) 1999-06-18 2006-09-20 Research Foundation Of State University Of New York Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
US7045134B2 (en) 2000-10-24 2006-05-16 University Of Medicine And Dentistry Of New Jersey Borellia burgdorferi epitope peptides
US6913936B2 (en) 2000-10-24 2005-07-05 University Of Medicine And Dentistry Of New Jersey Immunological test kit comprising an immunologically invisible peg copolymer conjugated to one or more immunologically reactive substances
US20030040127A1 (en) * 2000-10-24 2003-02-27 Bo Qiu Multiple epitopes connected by a carrier
AU2002259117A1 (en) * 2001-05-03 2002-11-18 Immunetics, Inc. Systems and methods for detection of analytes in biological fluids
US7262019B2 (en) 2001-05-03 2007-08-28 Immunetics, Inc. System and methods for detection of Bacillus anthracis related analytes in biological fluids
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
PL2199303T3 (pl) 2008-12-12 2013-11-29 Euroimmun Medizinische Labordiagnostika Ag Polipeptydy i sposoby swoistego wykrywania przeciwciał u pacjentów z zakażeniem krętkami Borrelia
US8946393B2 (en) 2010-09-27 2015-02-03 Cornell University Methods for diagnosing lyme disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) * 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
WO1994025596A2 (en) * 1993-04-29 1994-11-10 Immuno Aktiengesellschaft IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Also Published As

Publication number Publication date
DE69718903D1 (de) 2003-03-13
WO1997042221A1 (en) 1997-11-13
DE896583T1 (de) 2000-03-09
EP0896583B1 (de) 2003-02-05
EP0896583A1 (de) 1999-02-17
DK0896583T3 (da) 2003-05-26
CA2253374C (en) 2004-07-20
CA2253374A1 (en) 1997-11-13
DE69718903T2 (de) 2003-12-04

Similar Documents

Publication Publication Date Title
ATE232212T1 (de) Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
BR0015137A (pt) Peptìdeos antigênicos de neisseria
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
ATE247173T1 (de) Charakterisierung von polypeptiden
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
CA2175567A1 (en) Chimeric proteins comprising borrelia polypeptides: uses therefor
CA2216425A1 (en) Tetanus toxin functional fragment antigen and tetanus vaccine
Henschen et al. Sequence homology between γ-chain and β-chain in human fibrin
Niemann et al. Amino-terminal sequence of human factor B of the alternative complement pathway and its cleavage fragments, Ba and Bb
ATE159546T1 (de) Allergene aus roggenspreupollen
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
WO2000029434A3 (en) PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
Hong et al. Isolation and characterization of a soluble, immunoactive peptide of glial fibrillary acidic protein
WO2003070768A3 (en) Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
GR3015244T3 (en) HIV related peptides.
Yang et al. Determination of the molecular mass of apolipoprotein B-100 A chemical approach
Nowack et al. Isolation of a procollagen peptide from amniotic fluid
WO2003064446A3 (en) Plasma protein-binding peptides from bacterial curli
Besada et al. Mass spectrometry in protein analysis.
Kehl et al. Characterisation of rat fibrinogen
HUP0001462A2 (en) Human toll-like receptor proteins, related reagents and methods
Grant et al. Mapping Functional Domains of Human Platelet Thrombospondin with Electro-Blotting and High Sensitivity Sequencing
NZ311874A (en) Recombinant and/or pure preparations of H. pylori polypeptides and nucleic acids which are useful for diagnostics and vaccines
SE0002738D0 (sv) Electric actuator

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0896583

Country of ref document: EP

EEIH Change in the person of patent owner